Press Releases for BMRN

Press Releases
Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
BioMarin Announces Second Quarter 2009 Financial Results
Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome
BioMarin to Host Second Quarter 2009 Financial Results Conference Call and Webcast on Thursday, July 30 at 5:00 p.m. ET (23:00 CET)
Richard A. Meier Appointed to STAAR Surgical Board of Directors
Kuvan Receives Priority Review Status From Health Canada
BioMarin to Present at the Jefferies Healthcare Conference
Results From Phase 1 Clinical Study of PEG-PAL in PKU and Update on Phase 2 Clinical Study
BioMarin to Present at the William Blair Growth Stock Conference
BioMarin to Present at the Goldman Sachs Healthcare Conference
BioMarin Receives 2009 Corporate Award for the Development of Kuvan
BioMarin to Present at the Deutsche Bank Health Care Conference
BioMarin to Present at the Baird Growth Stock Conference
BioMarin Announces First Quarter 2009 Financial Results
BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
BioMarin to Present at the 4th Annual Citi Biotech Day
BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA
BioMarin to Present at the Cowen and Company 29th Annual Health Care Conference
BioMarin to Present at the Barclays Capital Global Healthcare Conference
FDA Warning Letter to Genzyme Related to the Allston Manufacturing Facility
BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer
BioMarin Supports Observance of Rare Disease Day February 28
Zacks Analyst Blog Highlights: Motorola, Hewlett-Packard Company, BioMarin Pharmaceutical Inc., Jet Blue and Embraer Air.
BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Results of First Interim Efficacy Analysis for Riquent Phase 3 ASPEN Trial: Continuation of the Trial is Futile
Naglazyme Approved by Brazil's National Health Surveillance Agency
Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
BenchmarkJournal.Com (Complimentary) Analyst Review for CELG, SIAL, BMRN and BEAV
BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
BioMarin to Present at the 27th Annual J.P. Morgan Healthcare Conference
BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
Kuvan Receives Marketing Approval in the European Union
BioMarin to Present at the Piper Jaffray Healthcare Conference
BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
Data to Be Presented at 58th Annual Meeting of The American Society of Human Genetics
BioMarin to Present at the Credit Suisse Healthcare Conference
BioMarin Announces Initiation of Clinical Assessment Program for Morquio A Syndrome
BioMarin Announces Third Quarter 2008 Financial Results
BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
BioMarin Opens Office in Brisbane to Support Expanding Operations
BioMarin to Host Third Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, October 28 at 5:00 p.m. ET (23:00 CET)
Kuvan Receives Positive Opinion From CHMP for European Approval
BioMarin Corrects Information Included in Bloomberg Article
William Blair & Company Initiates Coverage of BioMarin Pharmaceutical Inc. With Outperform Rating
BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
Seven Summits Research Releases Alerts on MRK, ADBE, STP, ADM, and BMRN
BioMarin to Present at the Citi Biotech Day
BioMarin to Present at the Morgan Stanley Global Healthcare Conference
BioMarin Announces Roll-Out of National PKU Registry
BioMarin Announces Second Quarter 2008 Financial Results
BioMarin and Summit plc Sign Worldwide Licensing Agreement for Duchenne Muscular Dystrophy Program
Biopten (Sapropterin Dihydrochloride) Approved by Japanese Ministry of Health for the Treatment of PKU
BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
BeaconEquity.com Issues TraderNotes on Active Stocks: LAUD, RMBS, ARTE, FRPT, SONS, EBAY, BMRN, ICOG
BioMarin to Present at the Collins Stewart Growth Conference
BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
BioMarin to Host Research and Development Day June 5th - May 27 2008 1:02AM
BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU - May 27 2008 12:58AM
BioMarin to Present at the Bank of America Healthcare Conference - Jun 1 2008 11:00AM
BellwetherReport.com Initiates Analyst Coverage on BMRN, ARRS, SVVS and FSLR - May 27 2008 1:16AM
Seven Summits Research Releases Comments on AAPL, VLO, SAP, IP, and BMRN - May 27 2008 1:16AM
BioMarin Announces First Quarter 2008 Financial Results
BioMarin to Present at the Morgan Stanley Healthcare Conference
BioMarin to Host First Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, April 29 at 5:00 p.m. ET (23:00 CET)